Show simple item record

dc.contributor.author Kovaltchouk, Uliana
dc.date.accessioned 2018-07-10T19:28:03Z
dc.date.available 2018-07-10T19:28:03Z
dc.date.issued 2016
dc.date.submitted 2018-07-10T19:28:03Z en
dc.identifier.uri http://hdl.handle.net/1993/33107
dc.description.abstract Immunobullous diseases result from an autoimmune process in which the targets are antigens in the skin. Therapy has classically included systemic steroid and other immunosuppressants including Mycophenalate mofitil, azathioprine, and other immunosuppressant medications. Chronic use of such immunosuppressives, over the years, can often result in suppression of such disease. Rituximab, a monoclonal anti-body, has shown great promise as remittive management of immunobullous diseases. Such medications have been extensively utilized at our clinic in management of such patients. We undertake a retrospective project to characterize and classify the patient demographics, disease specific, and treatment regimen that these patients required, to gain a better understanding of the utility of Rituximab in the management of this patient population. en_US
dc.subject Immunobullous diseases en_US
dc.subject autoimmune skin disorders en_US
dc.title iMMUNOBUllous disease and the efficacy of rituximab: A manitoba population analysis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics